CAJ | 학술논문

目的：比较雷替曲塞联合奥沙利铂方案与XELOX方案治疗晚期结直肠癌的临床疗效及安全性，为结直肠癌的临床治疗提供更多的参考依据。方法选择本院临床肿瘤中心化疗病区收治的晚期结直肠癌患者79例，随机分为研究组（39例）和对照组（40例）。研究组患者予以雷替曲塞联合奥沙利铂方案治疗，对照组则以XELOX方案治疗，观察治疗后两组患者的临床疗效及不良反应的发生情况。结果研究组与对照组分别有32例和30例患者可评价临床疗效，总有效率分别为53.13％和50.0％；中位疾病进展时间分别为8.1个月与8.9个月，两组的临床疗效差异无统计学意义（P>0.05）。研究组血液学毒性如中性粒细胞减少的发生率高于对照组，差异具有统计学意义（P<0.05）；非血液学毒性如手足综合征、腹泻等的发生率均显著低于对照组，差异具有统计学意义（P<0.05）。结论雷替曲塞联合奥沙利铂治疗晚期结直肠癌的临床疗效与XELOX方案相当，但安全性更高，用药更方便。
목적：비교뢰체곡새연합오사리박방안여XELOX방안치료만기결직장암적림상료효급안전성，위결직장암적림상치료제공경다적삼고의거。방법선택본원림상종류중심화료병구수치적만기결직장암환자79례，수궤분위연구조（39례）화대조조（40례）。연구조환자여이뢰체곡새연합오사리박방안치료，대조조칙이XELOX방안치료，관찰치료후량조환자적림상료효급불량반응적발생정황。결과연구조여대조조분별유32례화30례환자가평개림상료효，총유효솔분별위53.13％화50.0％；중위질병진전시간분별위8.1개월여8.9개월，량조적림상료효차이무통계학의의（P>0.05）。연구조혈액학독성여중성립세포감소적발생솔고우대조조，차이구유통계학의의（P<0.05）；비혈액학독성여수족종합정、복사등적발생솔균현저저우대조조，차이구유통계학의의（P<0.05）。결론뢰체곡새연합오사리박치료만기결직장암적림상료효여XELOX방안상당，단안전성경고，용약경방편。
Objective To compare the clinical efficacy and safety of raltitrexed plus oxaliplatin program and XELOX regimen for patients with advanced colorectal cancer, and provide more evidences for the clinical treatment of colorec-tal cancer. Methods A total of 79 patients with advanced colorectal cancer admitted in the chemotherapy ward of clinical oncology center in our hospital were selected and randomly divided into the study group (39 cases) and control group (40 cases) according to different therapeutic regimens. The study group was treated by raltitrexed plus oxaliplatin regimen, while the control group was given XELOX regimen. A treatment cycle included 21 days. The clinical efficacy and inci-dence of adverse reactions such as vomiting, loss of appetite and so on were observed and compared between the two groups. Results There were respectively 32 cases and 30 cases in the study group and control group whose clinical efficacy could be evaluated, with a respective clinical efficacy of 53.13%and 50.0%. The median time to progression was 8.1 months in the study group and 8.9 months in the control group. No significant differences were found in the clinical efficacy between the two groups (P>0.05). The incidence rate of hematologic toxicity of the study group such as neutropenia was higher than that of the control group, and difference was statistically significant (P<0.05). The incidence rates of other adverse reactions such as hand-foot syndrome and diarrhea were significantly lower than those of the control group (P<0.05). Conclusion Raltitrexed combined with oxaliplatin regimen for patients with advanced colorectal cancer had equivalent clinical efficacy of XELOX regimen, but it is more secure and more convenient in medication.